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Abstract
Background: Cancer as a multistage process can be reversed or blocked by using chemopreventive agents. Colon
cancer chemoprevention has been widely investigated using cyclooxygenase inhibitors and many other chemicals
of synthetic or natural origin. This particular study was carried out to assess the colon cancer chemopreventive
effect of hydro-methanol extract of Rumex abyssinicus rhizome on rats.
Method: Colon cancer chemopreventive potential of hydro-methanol extract of Rumex abyssinicus rhizome was
determined based on the number and multiplicity of aberrant crypt foci (ACF). Fifteen DMH (1, 2-dimethylhydrazine)
treated and five untreated Wistar female rats were used. DMH was administered subcutaneously 30 mg/kg, after its pH
was adjusted to 6.5–7. Treatment groups started receiving extract after six weeks of weekly DMH injections. The rats
were divided in to four groups: Group 1 received only oral normal saline, Group 2 received DMH and normal saline,
Group 3 and 4 received DMH plus 250 mg/kg and 500 mg/kg extract, respectively. Specific phytoconstituents of the
plant, which were reviewed from original articles, were virtually evaluated for cyclooxygenase-2 (COX-2) inhibition. The
binding energies and interactions of the phytochemicals from Rumex abyssinicus against COX-2 were determined by
Autodock4.2.
Results: There was a statistically significant reduction (p-value < 0.05) in the number of aberrant crypt (AC) and aberrant
crypt foci (ACF) at both administered doses. However, significant association (p-value > 0.05) was not observed in reducing
crypt multiplicity. The docking process resulted in estimated binding energies [−6.83 kcal/mol to −7.9 kcal/mol] which are
closer to the positive controls or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [−4.55 kcal/mol to −10.84 kcal/mol].
The phytochemical-COX-2 interaction indicated the involvement of key amino acid residues in inhibition of
cyclooxygenase like ARG120, TYR355, TYR385, SER530 and GLY526.
Conclusions: Rumex abyssinicus had demonstrated a chemopreventive potential at post-initiation stage. As the virtual
screening data suggested, COX-2 inhibition by the anthraquinones in the extract could be one mechanism for the
observed chemopreventive effect.
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Background
Colorectal cancer is one of the leading causes of cancer-
related mortality globally. Therefore, it is a major public
health challenge [1]. Curative and palliative therapies of
colon cancer have commonly relied on surgery, chemo-
therapy and radiotherapy [2]. Apart from these major
strategies, a relatively recent fourth method, which is
called chemoprevention, is being pursued. It is the use
of natural or synthetic compounds to block, reverse, or
prevent the development of invasive cancers [3]. Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs) has been
widely studied for chemoprevention of colon cancer.
Despite their effectiveness, gastrointestinal perforation
due to non-selective inhibition of cyclooxygenase enzymes
has limited their use [4]. Even selective cyclooxygenase-2
(COX-2) inhibitors such as Celecoxib were removed from
the market due to increased risk of heart attack and stroke
[5]. Regardless of the challenges faced so far, COX-2
enzyme remains a prominent target for the development
of chemopreventive agents. Natural products have also
attracted great interest as a potential source of chemopre-
ventive agents. Certain clinical trials and numerous
in vitro studies showed phytoconstiuents like curcumin to
have chemopreventive efficacy against colorectal cancer
[2]. In eight weeks post-initiation animal study, red
ginseng significantly reduced the incidence of ACF, which
indicates potential for colon cancer chemoprevention [6].
Rumex abyssinicus Jacq (polygonaceae) is a large
annual herb up to 4 m high. Its local Amharic name is
‘Mekmako’ [7]. In Ethiopia, it has been traditionally used
for management of hypertension, inflammatory and
painful conditions [8]. Polygonacea family and the genus
Rumex, to which the study plant belongs, are rich in
polyphenols like anthraquinones, flavanoids and terpens
[9]. In particular, different studies found that Rumex abys-
sinicus to contain a number of anthraquinones [10–12]. In
separate studies, some anthraquinones, which are also
found in Rumex abyssinicus, showed COX-2 inhibitory
activity [13, 14]. It has also been shown to have strong
anti-inflammatory property, which indicates its potential
as source of chemopreventive agents [15, 16]. In addition,
extracts of Rumex abyssinicus and other Rumex species
have shown antitumor activity against different cancer cell
lines [17–19].
It is believed that inflammation is intimately linked to
carcinogenesis. Over-expression of COX-2 is thought to be
an early event in colon carcinogenesis and the develop-
ment of other epithelial tumors. Thus, agents with anti-
inflammatory properties and cyclooxygenase inhibition like
NSAIDs are likely to exert chemopreventive action [6, 20].
Accordingly, we evaluated Rumex abyssinicus for colon
cancer chemoprevention because of traditional claims and
evidences of strong anti-inflammatory action plus evi-
dences of potential cyclooxygenase inhibition.
In this study, we evaluated the colon cancer che-
mopreventive ability of crude hydro-methanol extract of
Rumex abyssinicus. We used putative biomarkers of
colon cancer named aberrant crypt foci to evaluate effi-
cacy as a chemopreventive agent. In addition, we per-
formed virtual screening of most abundant secondary
metabolites of the plant like the anthraquinones against
the commonly studied target COX-2. In doing so, we





Wistar female rats weighing 200–300 g were used in this
experiment. The rats were housed in a group of five per
cage in a standard polyethylene cage. They were kept
under ambient temperature and humidity. Day and night
cycle was maintained at 12 h each. Food and drinking
water were provided ad libitum. Body weights were
monitored weekly throughout the study period. After
acclimatization for a week, the rats were divided in to
four groups, five in each group.
Plant materials
Collection and extraction of plant material
The rhizomes of Rumex abyssinicus were collected from
Addis Ababa. Then, a specimen was authenticated and
deposited by National Herbarium, Biology Department,
Addis Ababa University. The rhizomes were sliced to
smaller pieces and dried at room temperature under
shade. The pieces were then powdered and extracted. A
kilo of powdered rhizome was divided in to four batches,
and each batch was placed in a 5 L conical flask. Next,
80 % methanol was added to each flask up to a volume
sufficient to fully cover the powder inside. It was left to
macerate for 48 h with occasional shaking. The extract
was then filtered and, the marc was re-macerated twice
using the same solvent to exhaustively extract metabo-
lites. The methanol and water, in the extract, were re-
moved by rota vapour and lyophilizer, respectively.
Finally, the dried extract was packed in a plastic bag and
stored in a dry place at room temperature. The percent-
age yield of dried extract was found to be 16.4 % (w/w).
Dosing of extract
The dose selection was made based on a previous study
on the diuretic and analgesic effect of Rumex abyssinicus.
The dose used to produce analgesic effect was selected, as
it may be linked with the anti-inflammatory activity of the
extract. Accordingly, doses of 250 mg/kg and 500 mg/kg
were considered. The rats were expected to tolerate the
doses; because a preliminary study of 15 days found no
acute toxicity and the lethal dose 50 (LD50) was greater
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than 5000 mg/kg [21]. Dose was calculated for individual
rats based on their weekly weight which was taken at the
beginning of each week. The dried extract was re-
constituted in normal saline (0.9 % NaCl). A 100 ml stock
solution with strength of 0.1 g/ml (w/v) was freshly pre-
pared twice a week for the entire experiment.
ACF induction
DMH was prepared immediately before use, dissolved in
0.9 % NaCl containing 1.5 % EDTA as a vehicle at a final
concentration of 10 mg/ml. The pH was adjusted to
6.5–7 with sodium hydroxide to ensure the stability of
the chemical. The preparation was given subcutaneously,
once a week, at a dose of 30 mg/kg body weight for six
weeks to all except negative controls [22, 23].
Experimental protocol
The experiment was conducted for twelve weeks, after
which all rats were killed by cervical decapitation. This
method was intended to observe the effect of the extract
on the progress of pre-neoplastic lesions. Thus, the ex-
tract administration was commenced six weeks after the
first injection of DMH.
Treatment schedule
Group 1: Only 1.5 ml of Normal saline p.o everyday for
six weeks.
Group 2: DMH (30 mg/kg body weight once a week
s.c. for six weeks) + 1.5 ml of Normal saline p.o everyday
for six weeks.
Group 3: DMH (30 mg/kg body weight once a week
s.c. for six weeks) followed by Extract (250 mg/kg
body weight in normal saline p.o starting six weeks
after the first DMH injection till the end of 12th
week) (POST- INITIATION— PI).
Group 4: DMH (30 mg/kg body weight once a week
s.c. for six weeks) followed by Extract (500 mg/kg
body weight in normal saline p.o starting six weeks
after the first DMH injection till the end of 12th week)
(POST- INITIATION— PI).
ACF scoring
The colons were evaluated for ACF according to Bird’s
procedure. Each segments of the rats’ colons was fixed
flat between filter papers in 10 % buffered formalin for
at least for 24 h and then stained with methylene blue
(0.2 % in saline) right before visualization. Staining was
allowed to continue to 5–10mins. Finally, the aberrant
morphology was observed at 40× magnifications using a
light microscope with the mucosal side uppermost. ACF
were distinguished from the surrounding crypts by their
slit-like opening, elliptical shape, darker staining, in-
creased size and pericryptal zone [24]. Chemopreventive
response was assessed on the basis of AC, ACF, and
ACF multiplicity.
Statistical analysis
Statistical analysis of data sets was done with SPSS ver-
sion 16. Bivariate correlation was made using Pearson
correlation coefficient. Pair wise comparisons were made
using paired and independent t-tests. p- Value less than
0.05 were considered significant.
Limitation
Although virtual screening tools like autodock4.2 can
reasonably predict binding energies and activities of
ligands against different receptors, there are also a lot of
limitations to their abilities. Hence, any claim of activity
based on In silco studies needs to be backed by experi-
mental findings, which is also the case in this particular
study.
Ethical consideration
The handling of the animals was in accordance with the
ethical standards of using animal subjects. It was also
reviewed and approved by research ethics committee of
Pharmacology Department, School of Medicine, Addis
Ababa University.
Docking part
The docking was done by using free software called
Autodock4.2. The COX-2 [PDBe Code: 1CX2] enzyme
3D structure, which was used as a target receptor for
the phytochemicals, was downloaded from http://
www.ebi.ac.uk/pdbe/. Initially, we searched Google scho-
lar and Pubmed for studies, which isolated and charac-
terized specific phytochemicals of Rumex abyssinicus
rhizome. After collecting the relevant literatures, we ex-
tracted the compound names reported to make a prelim-
inary list. Then, the compounds in the list were reviewed
for their solubility in 80 % methanol and fulfillment of all
the criteria in Lipinski’s rule of five. Finally, a list of phyto-
constituents was produced that we used for the In silco
study. We downloaded the 3D structures of all the metab-
olites in the final list from PubChem. In addition, the 3D
structures of all the ten positive controls, which were
NSAIDs, were downloaded from PubChem. The pdb files
of the ligands were converted in to pdbqt formats using
‘Quick ligand’ option in Autodock. The pdbqt format of
the receptor was prepared by ‘Grid’ tab in the same tool.
The method was first validated by re-docking the
SC58 to monomeric form of COX-2 both of which were
obtained from the experimentally co-crystallized 1CX2
structure at 3 Å resolution. The docking was considered
valid, only if the reference root mean square deviation
(RMSD) was equal to or less than 2 Å [25]. Besides, the
re-docked complex was checked for the presence of
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same ligand-receptor interactions like H-bonding de-
scribed in the original literature. Further, the ability of the
docking method to predict activity was validated by cor-
relating the estimated binding energies from Autodock4.2
to experimental IC50 values of ten known COX-2 inhibi-
tors (Positive Controls).
The receptor binding site to which the ligands were
docked was defined by a grid box with X,Y,Z dimensions
of 60,60,60 points, spacing of 0.375 Å and a grid center
23.295, 22.171, 16.173. The default docking parameters
of Autodock4.2 were used except for the ga_run, which
was reset to 50 runs. The Lamarkian Genetic algorithm
was used as a search algorithm.
Results
Experimental part
This study investigated colon cancer chemopreventive
potential of 80 % methanol extract of Rumex abyssinicus
rhizome. We used 1, 2-dimethylhydrazine induced ACF
as surrogate biomarkers of colon cancer. Our experi-
ment assessed chemopreventive potential based on the
number and multiplicity of abnormal crypts.
All the rats that received the carcinogen developed the
pre-neoplastic lesions (N = 15). In the DMH only group
(G-II), the mean ± standard deviation (SD) of ACs, ACF
and crypt multiplicity was 103.60 ± 21.04, 24.80 ± 3.56
and 4.17 ± 0.64, respectively. Post- initiation group trea-
ted with 500 mg/kg extract (G-IV) showed the least
number of AC, ACF and multiplicity and those
treated with 250 g/kg (III) showed slightly greater
number of abnormal crypts than 500 mg/kg groups.
In comparison with the DMH only group, both the
intervention groups significantly reduced the number
of ACs and ACF (p-value < 0.001 for 250 mg/kg vs.
DMH only; p-value < 0.0001 for 500 mg/kg vs. DMH
only). The extract reduced the incidence of ACs and
ACF by more than fifty percent. However, none of
the treatment doses significantly reduced crypt multi-
plicity (p-value > 0.05 for 250 mg/kg or 500 mg/kg vs.
DMH only). Similarly, comparison of the two doses
didn’t show significant difference in terms of ACs as
well as ACF reduction (p-value > 0.05 for 500 mg/kg
vs. 250 mg/kg) (Table 1).
The mean weights of each group at the beginning and
end of experiment were 222 g and 242 g for group 1;
232 g and 241 g for group 2; 234 g and 242 g for group
3; 233 g and 247 g for group 4, respectively. We did a
paired t-test to identify if the extract given rats gained or
lost significant weight. The result showed that neither of
the treatment groups experienced significant weight
change between the beginning and end of the study
(p-value = 0.140 for 250 mg/kg; p-value = 0.128 for
500 mg/kg).
Docking part
The reviewing of literatures for specific phytochemicals
of Rumex abyssinicus, which can be extracted with a
hydro-methanol solvent, had resulted in nine com-
pounds. All the metabolites were anthraquinones. They
were Rhein, Chrysophanol, emodin, emodic acid, aloe-
emodin, alizarin, physcion, damnacanthal and catenarin
[10–12]. Lipinski’s rule of five, which can reasonably de-
termine the oral bioavailability of drugs, was fulfilled by
all the above mentioned compounds [26].
The re-docking of the SC58 to COX-2(1CX2) had re-
sulted in a RMSD value of 1.5 Å, which indicated the
success of the docking. The docking was also able to re-
produce all the experimentally determined hydrogen
bonds to the amino acid residues like HIS90, ARG513
and PHE518 (Fig. 1) [27]. Among the 50 runs only thirteen
(26 %) were able to show the above mentioned ligand-
receptor interaction. All the correct poses were found in
the bottom quarter of reference RMSD values. The valid-
ation of the method with positive controls (Celecoxib,
Aspirin, Meclofenamic acid, Ibuprofen, Flurbiprofen,
Indomethacin, Meloxicam, Piroxicam, Nilusemide and
Etodolac) had shown connection between estimated bind-
ing energy (ΔG) and activity. The –ΔG values from auto-
dock4.2 and negative logarithm of inhibitory concentration
50 (IC50) from William Harvey Human Modified Whole
Blood Assay (WHMA) had resulted in a statistically signifi-
cant (p-value = 0.003) positive correlation (r = 0.835) [28].
Table 1 Chemopreventive effect of hydro-methanol Rumex abyssinicus rhizome extract on the post-initiation of aberrant crypt foci
(ACF) in six weeks DMH treatment induced colon carcinogenesis
Animal group N Treatment AC ACF Crypt multiplicity
Mean ± SD Mean ± SD Mean ± SD
Group I 5 Saline 0 0 0
Group II 5 DMH 103.60 ± 21.04 24.80 ± 3.56 4.17 ± 0.64
Group III 5 PI 250 mg/kg + DMH 41.40 ± 9.66ac 11 ± 3.00ac 3.83 ± 0.39NSc
Group IV 5 PI 500 mg/kg + DMH 33.20 ± 6.14bc 8.80 ± 1.64ac 3.78 ± 0.19NSc
AC aberrant crypt, ACF aberrant crypt foci, crypt multiplicity the mean total of AC counted/mean total of ACF, DMH 1,2-dimethylhydrazine, N number of rats,
PI post-initiation, SD standard deviation
a, b, NSare all P-values where a< 0.001, b< 0.0001 and NS is not statistically significant
cPost-initiation 250 mg/kg OR post-initiation 500 mg/kg versus DMH
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The estimated binding energies of the positive
controls including the original ligand, SC58, ranged
from −4.55 kcal/mol to −10.84 kcal/mol. But, most
produced binding energies from −7 to −10 kcal/mol.
The binding energies of the phytochemicals were be-
tween −6.83 kcal/mol and −7.9 kcal/mol. Since the
re-docking indicated that right ligand-receptor interac-
tions were found in poses with relatively lower RMSD
(bottom quarter), we had considered most repeated inter-
actions of poses with RMSD in the lower 26 % as the cor-
rect ones. Consequently, the number of hydrogen bonds
between the phytochemicals and COX-2(1CX2) ranged
from zero to three. Except alizarin all compounds formed
hydrogen bonding with the enzyme. Amino acids such as
ARG120, TYR355, TYR385, SER530 and GLY526 were in-
volved in hydrogen bonding (Table 2).
Discussion
Carcinogenesis is a multistep process initiated from pre-
neoplastic cells [29]. Experiments using pre-neoplastic
lesions, which require less time to initiate carcinogenesis
and use fewer study animals, provide an excellent end
point to study chemopreventive agents [30]. In our
study, we considered pre-neoplastic lesions named ACF.
The exact correlation of ACF and colon cancer is not
quite clear. This has led to a number of investigations
using ACF to correlate with colon cancer in different
ways [31]. In the present study, we considered the
number of individual AC, ACF and ACF crypt multi-
plicity to predict effect on colon cancer. The extract
reduced AC and ACF significantly, which indicated it
chemopreventive potential. Nevertheless, it was unable
to significantly modify ACF multiplicity at any dose. It is
widely believed that larger ACF are more likely to pro-
gress to invasive cancer than smaller ones [32]. So, the
failure of the extract to truly influence the crypt multi-
plicity may hint an inferior chemopreventive ability.
Post initiation has more clinical relevance since it
helps identify substances that prove useful in preventing
the recurrence and progression of precursor lesions for
Fig. 1 Hydrogen bond interaction between the sulfonamide group of SC58 and three amino acid residues, HIS90, ARG513 and PHE518, of
Cyclooxygenase-2 (1CX2)
Table 2 Mean binding energies and interactions of docked







Rehin −7.91 3 ARG120, TYR355, TYR385
Catenarin −7.30 3 ARG120, TYR385, SER530
Emodin −7.27 3 ARG120, TYR385, SER530
Emodic acid −7.69 3 ARG120, TYR355, TYR385
Physcoin −7.84 3 ARG120, TYR385, SER530
Chrysophanol −7.48 1 GLY526
Damnacanthal −7.78 2 TYR355
Alizarin −6.83 nil NONE
Aloe-emodin −7.28 2 TYR355, GLY526
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colon cancer [33]. The significant reduction in AC and
ACF numbers by the extract after the initiation of
carcinogenesis could be attributed to its potent anti-
inflammatory properties, which also interferes with
prostaglandin synthesis [15, 16].
Inflammatory responses with COX-2 over expression
are widely being related with different carcinogenesis
steps of many cancers including colon [34]. Moreover,
COX-2 mediates cell proliferation through production of
free radicals. Generally, inhibition of these enzymes
prevents cell proliferation, angiogenesis and induces
apoptosis, and prevents formation of DNA adducts,
which are all important in ending or altering carcinogen-
esis [4]. The estimated binding energy of the anthraqui-
nones was very close and even sometimes greater than the
positive controls used. Rhein, physcion, damnacanthal and
emodic acid showed greater binding energy than known
NSAIDs like aspirin (ΔG= −4.55 kcal/mol), flurbiprofen
(ΔG= −7.35 kcal/mol), etodolac (ΔG= −7.46 kcal/mol)
and meclofenamic acid (ΔG= −7.53 kcal/mol). Given the
very strong correlation between estimated binding energy
and inhibitory activity (IC50) of the positive controls,
proximity of ΔG values of the plant metabolites may
indicate inhibitory potential. In addition, the ligands inter-
action to amino acids known to be involved in Cyclooxy-
genase inhibition by different NSAIDs such as ARG120,
TYR355, TYR385 and SER530 will substantiate claim of
COX-2 inhibition even more [35].
The above assertion was also observed in various ex-
periments, though findings were variable. An in vitro
assay which assessed COX-1 and COX-2 inhibition by
natural quinones found that specific agents like damna-
canthal were able to inhibit over 50 % of the COX-2 at
higher concentration. However, apart from few other
anthraquinones many of them were with little or no
cyclooxygenase inhibitory activity [36]. Contrary to the
previous study’s conclusion, a different evaluation had
found COX-2 inhibitory activity by chrysophanol [13].
Another in vitro assay had also reported COX-2 inhib-
ition by physcion and emodin obtained from Rumex
nepalensis. In fact, emodin inhibited 78.1 % of COX-2 at
25 μM concentration, which was fairly close to cele-
coxib’s inhibition (88.6 %) at the same concentration
[14]. All the above mentioned studies seem to agree on
the fact that there is weak or no COX-1 inhibition by
anthraquinones. This may be a huge advantage in pro-
moting safe chemoprevention unlike many NSAIDs which
can cause GI perforation due to COX-1 inhibition [4].
Finding a safe and effective chemopreventive agent is
the main challenge currently. Since tolerability can be
determined by observations such as clinical signs,
reductions in body weight or a decrease in food con-
sumption, perhaps, the lack of significant weight dis-
parity, within the interventions, before and after extract
administration, indicates tolerability of the doses and
also may be a small but positive sign of safety combined
with effectiveness used in the animals [37].
Conclusions
In conclusion, hydro-methanol extract of Rumex abyssi-
nicus rhizome demonstrated a chemopreventive poten-
tial, by effectively reducing the number of AC and ACF,
at tolerable doses. The anthraquinones, which showed
the potential to act as inhibitor of COX-2 and were
among the dominant compounds in this polar extract,
may alone or in combination have inhibited COX-2. But,
further in vitro studies are required to conclude if each
of the phytochemicals can truly inhibit the enzyme indi-
vidually or in combination. In addition, other polyphenols
like flavanoids, which are among the most commonly
found metabolites in Rumex abyssinicus, may have con-
tributed to the solid result either through the inhibition of
COX-2 or other mechanism.
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